Aura Biosciences reports Q1 EPS (40c), consensus (49c)

As of March 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $202.9M. The company believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into the second half of 2026. “Throughout Q1 2024, the Company made significant progress across our ocular and urologic oncology therapeutic area programs,” said CEO Elisabet de los Pinos. “Enrollment continues in our global Phase 3 CoMpass trial in early-stage choroidal melanoma, and we expect early Phase 1 data from our bladder cancer trial mid-2024. Aura is committed to changing the treatment paradigms in ocular and urologic oncology, both areas where patients desperately need novel therapies that can effectively treat the tumor and also preserve the function of the organ with cancer.”